Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — Investor Presentation (January 2024)
17 slides from Pulse Biosciences's investor presentation, Jan 9, 2024
Slide 1: Pulse Biosciences Investor Presentation January 2024
(D) Pulse Biosciences: dy Investor Presentation January 2024
Slide 2: Forward Looking Statements
Forward Looking Statements All statemeets i tis presentation that are not historical are frwardlocking statements, Including, among other things, statements relating to the effectveness of the Companys nsPFA tectnclogy and CelFx System to non-thermally clear cells while sparing adjacent nowcelidar t
Slide 3: Powering the next generation in bioelectric medicine with nsPFA technology
Powering the next generation in bioelectric medicine with Nanosecond Pulsed Field Ablation technology. {D) Pulse Biosciences:
Slide 4: Proven Leadership Team
Proven Leadership Team Renowned Scientific Expertise Dr. Gan Dunnington Chief Medical Officer : pains Kevin Danahy Darrin Uecker Mitch Levinson Chief Executive Officer & Chief Technology Officer & Chief strategy Officer y Dr. Niv Ad President Director ‘ Chief Science Officer, ius thamigé —-$fcoolsul
Slide 5: Accelerated Clinical Progress with CellFX nsPFA Devices
Accelerated Clinical Progress with CellFX nsPFA Devices Recently Achieved Milestones and Upcoming Clinical Timelines November 2023 December 2023 January 2024 February 2024 '@ Cardiac Clamp (AF) Cardiac Catheter (AF) Percutaneous Electrode (thyroid) (OD) Pulse Biosciences:
Slide 6: Positioned to Unlock the $8 Billion Cardiac Atrial Fibrillation (AF) Market
Positioned to Unlock the $8 Billion Cardiac Atrial Fibrillation (AF) Market Powering the next generation in bioelectric medicine with Nanosecond Pulsed Field Ablation (nsPFA) Technology (A) Robust Patent Portfolio Broad Medical Device Novel AF nsPFA Devices nsPFA enabled i surrounding the technology
Slide 7: Addressing the Entirety of the Growing AF Market
)) Pulse Biosciences: Addressing the Entirety of the Growing AF Market Global Atrial Fibrillation (AF) Disease State: AF Patients 2019: ~43M Global* >$8B \ Expected 2050: ~72M Global* Electrophysiology Market Surgical Ablation Potential to address 2M. >1M Catheter Ablations annual open-heart procedu
Slide 8: Differentiated Properties of nsPFA Energy Pulses
Differentiated Properties of nsPFA Energy Pulses Nanosecond pulses can be ~500 times shorter than microsecond pulses Asa result, nsPFA can require ~20 times less energy to ablate cardiac tissue I a Standard PFA devices coming to market use RF-Style rifleantly shorter designs and off-the-shelf genera
Slide 9: Advantages of nsPFA Technology
Advantages of nsPFA Technology Eliminating the substantial tradeoff between safety and efficacy (7) Cellfx nsPFA cardiac ablation catheter: Precisely focused, circumferential ablation targeted for pulmonary vein isolation na single 5 second application with CellFX nsPFA ) CellFX nsPFA cardiac ablati
Slide 10: Open Surgical Delivery of nsPFA Energy — Cardiac Ablation
Open Surgical Delivery of nsPFA Energy — Cardiac Ablation Bipolar damp Anonthermal cardiac ablation clamp capable of complete transmural ablations in under 3 seconds Initial preclinical studies have demonstrated speed, precision and transmurality up to ~25mm between electrodes * Collaborating with t
Slide 11: Cardiac Clamp Strategic Opportunity
Cardiac Clamp Strategic Opportunity High Strategic Value 1. Fast and Easy Market Entry 2. nsPFA Superior Product Offering 3. Ability to Prove Effectiveness for AF Prior to Catheter Launch 4, Provides Complete Solution 5. Sizable Revenue Opportunity Prior to Catheter Launch {D) PulseBiosciences: 1 ay
Slide 12: Catheter Delivery of nsPFA Energy — Cardiac Ablation
Catheter Delivery of nsPFA Energy — Cardiac Ablation Proprietary nsPFA-Optimized 2-Day Endocardial Surface ‘nSPFA Generator Platform 4 : Catheter Design “Sem Diameter * Circumferential ablation catheter enabled by nsPFA energy for single-shot PVI ablation * Reduced muscle spasm and nerve capture due
Slide 13: nsPFA Preclinical Evidence Supporting Safety, Tolerability and Effectiveness
nsPFA Preclinical Evidence Supporting Safety, Tolerability and Effectiveness Tolerance/Effectiveness Tolerance/Safety Tolerance/Effectiveness nsPFA can create clinically relevant nsPFA can create clinically relevant This electron microscopy study circumferential wide lesions with deep and wide lesio
Slide 14: Application Milestones for Treatment of AF
Application Milestones for Treatment of AF Recently Accelerated Development Timelines 2024 2025 2026 ———— 9 o_o surgical m i ——~ Catheter ‘ First-In-Human (OD) Pulse Biosciences:
Slide 15: Versatile Generator Platform Delivers nsPFA Across the Anatomy
Versatile Generator Platform Delivers nsPFA Across the Anatomy Enables rapid development of new applications Thyroid + Completed phase 1 enrollment of study, phase 2 in progress * Preclinical and clinical data demonstrating safety to collateral structures including nerves, vessels, trachea & esophag
Slide 16: Robust IP Portfolio
Robust IP Portfolio Wide and deep IP coverage of nsPFA energy & system Multipronged Patent Strategy » Pioneering IP for the use of nanosecond pulses in medicine Covering methods and tools for the application of nanosecond pulses in biology issued patents globally pwned & licensed * Continued develop
Slide 17: Pulse Biosciences regulatory and clinical status
ie _ Pulse Biosciences’ ™ ¥ CellFX nsPFA cardiac ablation clamp — filed FDA 510(k) submission December 2023 with plans to commercialize following clearance CellFX nsPFA cardiac ablation catheter — commenced first-in-human catheter ablation feasibility study in December 2023 with plans to expand enro
Pulse Biosciences — Investor Presentation (January 2024) on 6ix